Guggenheim analyst Michael Schmidt downgraded Blueprint Medicines (BPMC) to Neutral from Buy with a $132 price target after Sanofi (SNY) announced an agreement to acquire the company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls
- Blueprint Medicines downgraded to Equal Weight from Overweight at Stephens
- Blueprint downgraded to Market Perform from Outperform at Citizens JMP
- Blueprint Medicines downgraded to Hold from Buy at TD Cowen
- Blueprint downgraded to Peer Perform from Outperform at Wolfe Research